ALNY vs. DXCM: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALNY and DXCM, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
With ALNY at 38.15 billion USD and DXCM at 33.28 billion USD, their market capitalizations sit in the same ballpark.
DXCM carries a higher beta at 1.44, indicating it’s more sensitive to market moves, while ALNY remains steadier at 0.17.
| Symbol | ALNY | DXCM |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | DexCom, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Devices |
| CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. | Mr. Kevin Ronald Sayer |
| Price | 292.58 USD | 84.875 USD |
| Market Cap | 38.15 billion USD | 33.28 billion USD |
| Beta | 0.17 | 1.44 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | June 1, 2004 | April 14, 2005 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALNY and DXCM over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALNY and DXCM based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALNY posts a negative P/E of -140.68, reflecting last year’s net loss, while DXCM at 62.02 signals healthy earnings.
- ALNY posts a negative forward PEG of -38.16, hinting at anticipated earnings decline, whereas DXCM at 2.83 has projections for stable or growing earnings.
- ALNY has a negative Price-to-Free Cash Flow ratio of -506.05, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, DXCM (P/FCF 57.86) indicates positive free cash flow generation.
| Symbol | ALNY | DXCM |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -140.68 | 62.02 |
| Forward PEG Ratio (TTM) | -38.16 | 2.83 |
| Price-to-Sales Ratio (P/S, TTM) | 16.25 | 8.02 |
| Price-to-Book Ratio (P/B, TTM) | 328.68 | 14.65 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -506.05 | 57.86 |
| EV-to-EBITDA (TTM) | -251.73 | 39.29 |
| EV-to-Sales (TTM) | 16.37 | 8.43 |
| EV-to-Free Cash Flow (TTM) | -509.80 | 60.78 |
Dividend Comparison
Neither ALNY nor DXCM currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALNY | DXCM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALNY and DXCM, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ALNY is heavily leveraged (debt-to-equity ratio 11.28), which can boost returns but raises risk if borrowing costs climb, while DXCM at 1.14 keeps leverage at a more moderate level.
- With negative EBIT (-0.79), ALNY cannot cover its interest payments. DXCM, with an interest coverage of 43.93, meets its interest obligations.
| Symbol | ALNY | DXCM |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 1.50 |
| Quick Ratio (TTM) | 2.98 | 1.32 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 1.14 |
| Debt-to-Assets Ratio (TTM) | 0.31 | 0.38 |
| Interest Coverage Ratio (TTM) | -0.79 | 43.93 |